Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?
- PMID: 32305587
- PMCID: PMC7162746
- DOI: 10.1016/j.ijantimicag.2020.105988
Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?
Abstract
In the context of the ongoing global outbreak of coronavirus disease 2019 (COVID-19), management of exposure events is a concern. Long-term care hospitals (LTCHs) are particularly vulnerable to cluster outbreaks because facilities for patient isolation and healthcare personnel to care for these patients in isolation are difficult to arrange in a large outbreak situation. Although several drugs have been proposed as treatment options, there are no data on the effectiveness and safety of post-exposure prophylaxis (PEP) for COVID-19. After a large COVID-19 exposure event in an LTCH in Korea, PEP using hydroxychloroquine (HCQ) was administered to 211 individuals, including 189 patients and 22 careworkers, whose baseline polymerase chain reaction (PCR) tests for COVID-19 were negative. PEP was completed in 184 (97.4%) patients and 21 (95.5%) careworkers without serious adverse events. At the end of 14 days of quarantine, all follow-up PCR tests were negative. Based on our experience, further clinical studies are recommended for COVID-19 PEP.
Keywords: COVID-19; Hydroxychloroquine; Long-term care hospital; Post-exposure prophylaxis; SARS-CoV-2.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Figures

Similar articles
-
Hydroxychloroquine for post-exposure prophylaxis of COVID-19 among naval personnel in Sri Lanka: study protocol for a randomized, controlled trial.Trials. 2020 Aug 27;21(1):748. doi: 10.1186/s13063-020-04659-7. Trials. 2020. PMID: 32854751 Free PMC article.
-
COVID-19: Time for Post-Exposure Prophylaxis?Int J Environ Res Public Health. 2020 Jun 4;17(11):3997. doi: 10.3390/ijerph17113997. Int J Environ Res Public Health. 2020. PMID: 32512873 Free PMC article. Review.
-
Containment of a healthcare-associated COVID-19 outbreak in a university hospital in Seoul, Korea: A single-center experience.PLoS One. 2020 Aug 14;15(8):e0237692. doi: 10.1371/journal.pone.0237692. eCollection 2020. PLoS One. 2020. PMID: 32797094 Free PMC article.
-
Controversies over hydroxychloroquine in the prevention of SARS-CoV-2 infection put rheumatologists on the frontline.RMD Open. 2020 Oct;6(3):e001323. doi: 10.1136/rmdopen-2020-001323. RMD Open. 2020. PMID: 33087414 Free PMC article. No abstract available.
-
Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say?Indian J Public Health. 2020 Jun;64(Supplement):S125-S127. doi: 10.4103/ijph.IJPH_496_20. Indian J Public Health. 2020. PMID: 32496241 Review.
Cited by
-
Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection.Expert Rev Anti Infect Ther. 2021 Jan;19(1):5-16. doi: 10.1080/14787210.2020.1799785. Epub 2020 Aug 16. Expert Rev Anti Infect Ther. 2021. PMID: 32693652 Free PMC article.
-
Maoto, a traditional herbal medicine, for post-exposure prophylaxis for Japanese healthcare workers exposed to COVID-19: A single center study.J Infect Chemother. 2022 Jul;28(7):907-911. doi: 10.1016/j.jiac.2022.03.014. Epub 2022 Mar 21. J Infect Chemother. 2022. PMID: 35361537 Free PMC article.
-
Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.J Clin Pharm Ther. 2021 Feb;46(1):17-27. doi: 10.1111/jcpt.13267. Epub 2020 Sep 27. J Clin Pharm Ther. 2021. PMID: 32981089 Free PMC article. Review.
-
A pharmacological perspective of chloroquine in SARS-CoV-2 infection: An old drug for the fight against a new coronavirus?Int J Antimicrob Agents. 2020 Sep;56(3):106078. doi: 10.1016/j.ijantimicag.2020.106078. Epub 2020 Jul 4. Int J Antimicrob Agents. 2020. PMID: 32629115 Free PMC article. Review.
-
Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19.Indian J Med Res. 2020 May;151(5):459-467. doi: 10.4103/ijmr.IJMR_2234_20. Indian J Med Res. 2020. PMID: 32611916 Free PMC article.
References
-
- Korean Society of Infectious Diseases KSoPID, Korean Society of Epidemiology, Korean Society for Antimicrobial Therapy, Korean Society for Healthcare-associated Infection Control and Prevention, and Korea Centers for Disease Control and Prevention Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020;35:e112. - PMC - PubMed
-
- Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquinone for the treatment of severe acute respiratory syndrome coronarvirus 2 (SARS-CoV-2) Clin Infect Dis. 2020 Mar 9 doi: 10.1093/cid/ciaa237. ciaa237. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous